Influence of type of treatment on the well-being of Spanish patients with schizophrenia and their caregivers

Abstract

Objective. This study aimed to investigate quality of life and burden on caregivers in Spanish outpatients with schizophrenia, treated with different antipsychotics. Methods. Sociodemographic and clinical data were collected for 1865 patients diagnosed with schizophrenia. Patients answered the EuroQol-5D questionnaire and caregivers answered questionnaires assessing caregiver burden. Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression of Severity (CGI-S), and clinician's satisfaction were also recorded. The same data were also collected at months 3 and 6. Results. According to EQ-5D results, usual activities (29.6%) and anxiety/depression (31.1%) were the most relevant reported problems. Good overall scores (5–7) on EQ-5D were reported by 47/118 (39.8%) of risperidone long-acting injectable (LAI) patients compared to 52/218 (23.9%) for oral conventional antipsychotics, 51/194 (26.2%) for injectable conventional antipsychotics, and 332/1110 (29.9%) for oral atypical antipsychotics. Significant benefits of risperidone LAI vs. other types of antipsychotic were also found in caregiver burden and clinician-derived outcome measures. At months 3 and 6, retention was > 85%, and score on the EQ5D improved for the overall sample. Conclusions. In Spanish patients with schizophrenia, activities of daily living and anxiety/depression were more relevant reported problems. Risperidone LAI was associated with better quality-of-life outcomes and lower caregiver burden compared to other types of antipsychotic.

Key Words::

• Schizophrenia
• caregivers
• risperidone

Acknowledgments

The authors thank Content Ed Net Madrid, for editorial assistance.

Statement of Interest

María Fé Bravo Ortiz has been involved in and participated in clinical trials for Janssen Cilag, has received educational grants for research, honoraria and travel support for activities as a consultant and lecturer for the Spanish Ministry of Health (FIS), Complutense University, Autonoma University, UNED, Salamanca University, Reunions i Ciencia, IAS Girona, AstraZeneca and Almirall. Alexander Rodriguez-Morales is the Group Medical Affairs Manager of Psychiatry and Dermatology of the Medical Department of Janssen-Cilag and owns stock in Johnson & Johnson. Rebeca Hidalgo Borrajo at the time of the study/manuscript was the Medical Affairs Manager of Psychiatry of the Medical Department of Janssen-Cilag. The authors have no other competing financial interests. The Alliance study was funded by a grant from Janssen Cilag Spain.